Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Jayasree K. Iyer to speak at The Economist Antimicrobial Resistance Summit

On 26 March 2019, Jayasree K. Iyer will join a panel discussion on private sector investment in antibiotics at The Economist magazine's Antimicrobial Resistance Summit. 

Date

26 March 2019

In a classic market failure, ageing antibiotics that are no longer effective are not being replaced by new ones. The traditional model of volume-based reimbursement is failing and antibiotic pipelines remain weak. 

Jayasree will join a panel titled 'The (private sector) investment conundrum' where she will discuss why pharma companies are no longer investing in developing new antibiotics, which of the incentives designed to reward successful antibiotic R&D shows the most potential, and how they can be made to work. 

Little progress has been made since the special declaration on antimicrobial resistance (AMR) at the UN General Assembly in September 2016. Yet the risk of returning to a pre-antibiotic era remains real. This event, organised by The Economist, will bring together over 120 health policy leaders, academics and industry experts to discuss how to galvanise support for the global fight against AMR.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved